14Jul/13

Dr Reddy's Labs scrip outperforms BSEHC, touches yearly high of – pharmabiz.com


pharmabiz.com

Dr Reddy’s Labs scrip outperforms BSEHC, touches yearly high of
pharmabiz.com
DRL has already pushed four biosimilars viz, rituximab, filgrastim, darbepoetin alpha and peg-filgrastim in the market. To consolidate its position in biosimilars, DRL entered into an alliance with Merck Serono, a division of Merck KGaA, Germany during

and more »

11Jul/13

Janssen whizzes promising CLL agent over to regulators – Medical Marketing and Media

Janssen whizzes promising CLL agent over to regulators
Medical Marketing and Media
Gilead’s candidate, idelalisib, was tested in combination with rituximab in treatment-naïve patients with CLL. That regimen achieved a compete response rate of 19% and an overall response rate of 97% in patients. AbbVie’s contender, ABT-199, which Yee 

and more »